These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Management of a patient with borderline resectable pancreatic cancer. Case report and review. Shah AP; Strauss JB; Leslie WT; Shah A; Mahon B; Abrams RA Oncology (Williston Park); 2008 Nov; 22(13):1524-9. PubMed ID: 19133606 [TBL] [Abstract][Full Text] [Related]
3. [Chemoradiation for pancreatic adenocarcinoma]. Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252 [TBL] [Abstract][Full Text] [Related]
4. [Chemotherapy, chemoradiotherapy or observation after complete resection of pancreatic adenocarcinoma?]. Lluís F Gastroenterol Hepatol; 2009 Feb; 32(2):120-1. PubMed ID: 19231687 [No Abstract] [Full Text] [Related]
5. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266 [TBL] [Abstract][Full Text] [Related]
6. The treatment of pancreatic cancer. Yeo CJ; Cameron JL Ann Chir Gynaecol; 2000; 89(3):225-33. PubMed ID: 11079793 [No Abstract] [Full Text] [Related]
7. Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer. Vento P; Mustonen H; Joensuu T; Kärkkäinen P; Kivilaakso E; Kiviluoto T World J Gastroenterol; 2007 Jun; 13(21):2945-51. PubMed ID: 17589944 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant and neoadjuvant therapy in curable pancreatic cancer. Nugent FW; Stuart K Surg Clin North Am; 2010 Apr; 90(2):323-39. PubMed ID: 20362789 [TBL] [Abstract][Full Text] [Related]
10. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Allen AM; Zalupski MM; Robertson JM; Eckhauser FE; Simone D; Brown D; Hejna G; Normolle D; Lawrence TS; McGinn CJ Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1461-7. PubMed ID: 15275733 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Heinrich S; Schäfer M; Weber A; Hany TF; Bhure U; Pestalozzi BC; Clavien PA Ann Surg; 2008 Dec; 248(6):1014-22. PubMed ID: 19092346 [TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of pancreatic cancer. Collins A; Bloomston M Minerva Gastroenterol Dietol; 2009 Dec; 55(4):445-54. PubMed ID: 19942828 [TBL] [Abstract][Full Text] [Related]